Bafna Pharmaceuticals Ltd
NSE: BAFNAPH BSE: 532989
₹105.11
(-4.44%)
Sat, 14 Mar 2026, 08:22 am
Market Cap2.52B
PE Ratio25.74
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KBafna Pharmaceuticals Analysis
dividend
- Unable to evaluate Bafna Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Bafna Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Debt is covered by short term assets, assets are 1.1x debt.
- Bafna Pharmaceuticals's cash and other short term assets cover its long term commitments.
- Bafna Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- The level of debt compared to net worth has increased over the past 5 years (108.8% vs 291.3% today).
- Bafna Pharmaceuticals's level of debt (291.3%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Bafna Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Bansilal Bafna's remuneration is lower than average for companies of similar size in India.
- The tenure for the Bafna Pharmaceuticals management team is about average.
- Bansilal Bafna's compensation has increased whilst company is loss making.
misc
- Bafna Pharmaceuticals is not covered by any analysts.
- Bafna Pharmaceuticals has significant price volatility in the past 3 months.
past
- Unable to compare Bafna Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Bafna Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Bafna Pharmaceuticals has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Bafna Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Bafna Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Bafna Pharmaceuticals's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Bafna Pharmaceuticals is good value based on assets compared to the IN Pharmaceuticals industry average.
- NSEI:BAFNAPH is up 10.1% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:BAFNAPH is up 10.1% outperforming the market in India which returned 8% over the past month.
- Bafna Pharmaceuticals is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Bafna Pharmaceuticals is loss making, we can't compare the value of its earnings to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800